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Abstract: Poly(γ-benzyl-L-glutamate) (PBLG) derivatives are synthetic polypeptides for 
preparing nanoparticles with well controlled surface properties. The aim of this paper was to 
investigate the biodistribution of pegylated PBLG in rats. For this purpose, nanoparticles were 
prepared by a nanoprecipitation method using mixtures of different PBLG derivates, including a 
pegylated derivate to avoid mononuclear phagocyte system uptake. The morphology, size distri-
bution, and surface charge of the nanoparticles were investigated as a function of the amount of 
polymer employed for the preparation. Moderately polydispersed nanoparticles (polydispersity 
index less than 0.2) were obtained. Their size increased with polymer concentration. The zeta 
potential values were negative whatever the formulations. The availability of polyethylene glycol 
chains on the nanoparticles’ surface was confirmed by measuring the decrease in bovine serum 
albumin adsorption. For in vivo distribution studies, pegylated and nonpegylated nanoparticles 
were prepared with polymer mixtures containing PBLG-fluorescein isothiocyanate and imaged 
by fluorescence microscopy to measure their accumulation in liver and spleen tissues of rats 
after intravenous administration. Injection of stealth formulations resulted in negligible fluores-
cence in liver and spleen compared with nonpegylated formulations, which suggests that these 
nanoparticles are promising candidates as a stealth-type long-circulating drug carrier system 
and could be useful for active targeting of drugs while reducing systemic side effects.
Keywords: PBLG, physicochemical characterization, biodistribution, nanoparticles, pegylation
Introduction
Synthetic polypeptides are potential carriers for the delivery of drugs, owing to their low 
toxicity, biocompatibility, biodegradability, adjustable structures, and well controlled 
dimensions. Polypeptides can be conveniently synthesized using N-carboxyanhydrides 
(NCAs) by ring-opening polymerization, which utilizes a wide variety of monomers 
containing various functional side groups. Similar to natural polypeptides, these 
polymers possess the ability to self-assemble into well defined, ordered structures. 
The use of polypeptidic polymers in the preparation of nanoparticles for drug delivery 
and targeting is an attractive area in nanomedicine.1–3 Poly(γ-benzyl-L-glutamate) 
(PBLG), a synthetic and biodegradable polypeptide, has attracted attention for use 
in biomedical applications because various chemical moieties could be quite easily 
introduced into the structure of PBLG to form various copolymers.2 The functional 
side group of carboxyl (–COOH) in glutamic acid units can be modified by chemical 
reactions to form new molecular structures.4,5 As an alternative, copolymers can be 
obtained by initiating the polymer synthesis with a molecule of biological interest, 
such as a polyethylene glycol (PEG) chain or a cyclodextrin moiety.2 Further, it has International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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been demonstrated that multifunctionalized nanoparticles 
exhibiting interesting surface properties could be obtained 
by preparing nanoparticles from mixtures of these different 
derivates.
Injectable polymeric nanoparticles have received much 
attention. Their use can be seen to prolong the blood half-
life of drugs and increase their efficacy.6 Alternatively, they 
represent very attractive properties for targeting applications 
for improving the selectivity in drug delivery or for imaging 
purposes. These latter applications necessitate an efficient 
control of their body distribution. Such a distribution after 
intravenous (IV) injection is considerably influenced by 
their interactions with the biological environment and their 
physicochemical properties, including particle size, surface 
charge, morphology, and surface hydrophilicity.7–9 Their size 
can affect the biodistribution of intravascularly injected nano-
particles. Studies have shown that large nanoparticles are 
sequestered in the liver, consistent with observations in the 
spleen, whereas very small nanoparticles (less than 100 nm) 
can pass through the sinusoidal fenestrations in the liver and 
be entrapped by underlying parenchymal cells.10 The size of 
polymeric nanoparticles can be adjusted to some extent as it 
depends on the polymer type, molecular weight, and concen-
tration. Thus, to some extent, convenient particle size can be 
looked for by adjusting the polymer properties.11–13
Further, the potential of injectable polymeric nanopar-
ticles is compromised by their rapid elimination from the 
bloodstream and their accumulation in the tissues of the 
mononuclear phagocyte system (MPS), mainly the Kupffer 
cells in the liver and the spleen macrophages.14–16 This pre-
vents their application in controlled drug delivery and drug 
targeting to tissues other than the MPS.
The preferred method for the preparation of long-circulating 
nanoparticles is to modify their surface by adding hydrophilic 
polymers. PEG has been widely used for modifying the sur-
face of particles, leading to stealth-type (long-circulating) 
carriers.17–19 Pegylation simply refers to the decoration of a 
particle surface by PEG chains, which can be obtained through 
different methods such as physical adsorption, covalent 
grafting, or the self-assembling of PEG copolymers.20–22 
These PEG chains create a hydrophilic layer in the surface of 
the particles, which acts as a barrier that is able to block the 
adhesion of opsonins present in the blood serum so that the 
particles can remain camouflaged or invisible to phagocytic 
cells.15 Many different types of PEG-containing polymers have 
been tested for their ability to impart stealth characteristics 
to polymeric nanoparticles. Particularly, poly(lactide-co-
glycolide) (PLGA)-PEG and poly(lactide) (PLA)-PEG 
nanoparticles have been   extensively investigated for their 
potential as controlled and targeted drug delivery systems.23,24 
It has been shown that the IV administration of these nanopar-
ticles loaded with a drug in experimental animals results in 
prolonged drug residence in systemic blood circulation.25 For 
example, after IV administration, PLA-PEG and PLGA-PEG 
nanoparticles remain in the systemic circulation for days, 
whereas PLA and PLGA nanoparticles are removed from 
blood within a few minutes.26
Therefore, when conceiving original nanoparticles for 
targeting applications, it is not only necessary to adjust 
their morphology, generally looking for small particles, but 
also to prevent the opsonization phenomenon. Obviously, 
pegylation remains nowadays a very attractive strategy for 
achieving this goal. The aim of this study was to investigate 
the biodistribution and efficacy of the pegylation of recently 
developed multifunctional PBLG nanoparticles.2,27,28 For this 
purpose, nanoparticles were prepared by a nanoprecipitation 
method using mixtures of different PBLG derivates, includ-
ing a pegylated derivate, to avoid MPS uptake. Further, their 
distribution in tissues were investigated using fluorescein 
isothiocyanate (FITC) derivate-tagged nanoparticles after 
IV administration in rats, with a specific emphasis on their 
  affinity for liver and spleen tissues, known as the major organs 
involved in the capture of nanoparticles in vivo.
Materials and methods
Materials
N,N-dimethylformamide (DMF; Acros, Belgium, 99%) and 
benzylamine (Janssen Chimica, Belgium) were distilled 
under reduced pressure over BaO and KOH, respectively, 
and stored under argon atmosphere. γ-benzyl-L-glutamate 
NCA, from ISOCHEM-SNPE (France), was used as received. 
Methoxy poly (ethylene glycol)-amine (mPEG-NH2), 
Mw = 5000 gmol−1 from Shearwater Corporation (USA) 
was dried separately under vacuum over P2O5 at 30°C for 
24 hours. Benzylamine (Bnz) and FITC were purchased from 
Sigma-Aldrich (Germany). Water was purified by reverse 
osmosis (Milli-Q, Millipore, USA). All other solvents and 
chemicals used were of analytical grade.
synthesis of PBLg derivatives
Three different PBLG derivatives (PBLG-Bnz, PBLG-PEG, 
and PBLG-FITC) were synthesized by anionic ring-opening 
polymerization of NCA initiated by Bnz, mPEG-NH2, or 
FITC, respectively, in DMF.2,29 To sum up, N   millimoles of 
NCA were weighed under argon atmosphere in a degassed, 
three-necked, round-bottomed flask equipped with a International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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  thermometer, mechanical stirrer, and refrigerant with a silica 
gel guard and a bubble detector. NCA was dissolved in DMF 
at room temperature under mechanical stirring and argon flux. 
After about 10 minutes, the initiator solution was added and 
CO2 emission was observed. The reactions were conducted 
under argon atmosphere, and mixtures were stirred at 30°C 
until the characteristic Fourier transform infrared (FT-IR) 
NCA bands disappeared from the spectrum (Perkin-Elmer 
1750, Norwalk, USA). Further, the mixture was precipitated 
in an excess of cold diethyl ether. The precipitates were 
filtered, washed with diethyl ether, and finally dried under 
vacuum at 35°C for at least 12 hours. Polymer molecular 
weights were characterized by Ubbelohde viscometer 
(Schott Geraete GmbH, Germany) using the Mark–Houwink 
  equation ([η] = 1.58 × 10−5Mw1.35); intrinsic viscosity (η) was 
measured at 25°C. Furthermore, both copolymers (PBLG-
Bnz and PBLG-PEG) were dissolved in deuteriochloroform 
(CDCl3) in nuclear magnetic resonance (NMR) tubes, and 
1H-NMR spectras were recorded with a Bruker Advance 
(Bruker, Karlsruhe, Germany) spectrometer operated at 
400 MHz.
Preparation of nanoparticles
Nanoparticles were prepared with the different PBLG 
derivatives by a modified nanoprecipitation method either 
using pure copolymers or a mixture of the different copo-
lymers.27 FITC-labeled nanoparticles were prepared with 
PBLG-Bnz:PBLG-FITC and PBLG-PEG:PBLG-FITC 
polymer mixtures at the 80:20 ratio. Briefly, copolymers or 
copolymer mixtures were dissolved in 5 mL of tetrahydro-
furane at 30°C using different amounts (5, 10, 15, 20, 25 mg). 
This organic solution was added to 10 mL of Milli-Q water 
by dripping, under magnetic stirring, without the presence 
of any surfactant. The mixture was then transferred to a 
Teflon flask. The solvent was gently evaporated, at 30°C, 
under a light air flow. Nanoparticles were washed with 
5 mL of Milli-Q water, and finally the suspension was partly 
evaporated to yield 10 mL of nanoparticle suspension. The 
suspensions were kept at +4°C in capped glass vials before 
use. Furthermore, their stability under these conditions was 
checked on a 4-week period during which the samples were 
visually inspected and their physicochemical characteristics 
regularly measured.
Physicochemical characterization  
of nanoparticles
The average particle size and size polydispersity of 
the nanoparticles were determined by dynamic laser 
light scattering (Nanosizer Coulter N4 Plus®, Malvern 
Instruments, Malvern, UK). The ζ potential of the 
nanoparticles was measured in aqueous dispersion with a 
Zetasizer 4 (Malvern Instruments) at 25°C. Experimental 
values were the average of six different preparations. Fur-
ther, nanoparticles were imaged by transmission electron 
microscopy (TEM) (TEM-Philips EM 208, Orsay, France) 
operating at 80 kV, and images were acquired using a 
high-resolution camera (Advantage HR3/12GO4, AMT-
Hamamatsu, France).
Isothermal titration calorimetry (ITc) 
experiments
In accordance with a previously published method, an 
isothermal calorimeter titration apparatus (MicroCal Inc., 
USA) has been used to evaluate the capacity of nanopar-
ticles to avoid protein adsorption and therefore to confirm 
the presence of PEG chains at the surface of the nanopar-
ticles.2 Bovine serum albumin (BSA) was used, as it has a 
major representative globular protein present in the serum 
and is known for being easily adsorbed on polymeric 
surfaces. The ITC instrument was periodically calibrated 
either electrically using an internal electric heater or chemi-
cally by measuring the dilution enthalpy of methanol in 
water. This standard reaction was in agreement (1%–2%) 
with MicroCal constructor data. In a typical experiment, 
aliquots of 10 µL of a BSA solution (5.4 × 10−2 mM) filled 
into a syringe containing 283 µL were used to titrate a 
suspension of nanoparticles   (pegylated or nonpegylated) 
(2.7 × 10−2 mM) into the calorimetric cell and accurately 
thermostated at 37°C (310 K). Intervals between injections 
were 300 seconds, and agitation speed was 270 rpm. A 
control experiment was also performed, which consisted 
of successive injections of a BSA solution in the measur-
ing cell filled with Milli-Q water. The corresponding heat 
flow was recorded as a function of time and accounted for 
dilution effects or any possible conformational changes 
likely to occur during dilution.
FITc labeling and characterization  
of nanoparticles
Emission spectrum of water-diluted, FITC-labeled nano-
particles was recorded with a fluorescence/luminescence 
spectrophotometer (Perkin Elmer LS 50B, Beaconsfield, 
UK) at an excitation wavelength of 485 nm. Further, the 
fluorescence images of FITC-labeled nanoparticles were 
observed by confocal laser scanning microscopy (CLSM 
510, Carl Zeiss, Jena, Germany).International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Figure 1 1h-NMr spectra of PBLg-Bnz (A) and PBLg-Peg (B).
Abbreviations: Bnz, benzylamine; NMr, nuclear magnetic resonance; PBLg, poly(γ-benzyl-L-glutamate); Peg, polyethylene glycol.
Table 1 Molecular weights of synthesized polymers
Polymer Average molecular weight (g/mol)
Theoreticala Observed
PBLg-Bnz 50,000 46,300b
PBLg-Peg 60,000 50,000c
PBLg-FITc 60,000 43,300b
Notes: acalculated by considering the constitutional repeating units according to 
the initial ratio; bcalculated from viscosity measurements; ccalculated from 1h-NMr 
spectra.
Abbreviations: Bnz, benzylamine; FITC, fluorescein isothiocyanate; PBLG, poly(γ-
benzyl-L-glutamate); Peg, polyethylene glycol.
In vivo studies
Distribution studies were performed in vivo in Wistar Albino 
rats (weighing between 250 and 300 g) in   accordance with 
an approved specific protocol (Ege University Faculty 
of   Pharmacy Animal Ethics Committee [Protocol no: 
2008/6-1]). The animals were divided into three groups (six 
animals per group), including a control group (G1) and two 
trial groups (G2 and G3). Prior to the experiments, animals 
were anesthetized with light ether. Nanoparticles were steril-
ized by membrane filtration before the in vivo administra-
tion.30 The saline solution was injected to control group G1, 
and the two other groups, G2 and G3, received pegylated 
and nonpegylated nanoparticle suspensions (0.3 mg/mL), 
respectively. All animals had free access to food and water 
ad libitum after the IV injection in the tail vein. Twenty-four 
hours after administration, the animals were killed by cervical 
vertebrae dislocation, and their liver and spleen tissues were 
isolated. All organs were cut and then immediately embed-
ded in   Cryoblock (DiaPath,   Bergamo, Italy) and cryosec-
tioned (7 µm) by cryomicrotome (Leica CM 1900, Wetzlar, 
  Germany) at −60°C. Biopsies were spread on microscope 
glass slides, and analyses were carried out using an Olympus 
IX71 model fluorescence microscope (Olympus Optical, 
Tokyo, Japan) equipped with an Olympus DP71 digital 
camera (Olympus America Corp., Mellville, NY).
statistical analysis
Statistical analysis of the data was performed via analysis 
of variance (ANOVA) followed by Tukey’s multiple 
comparisons test. A P value of less than 0.05 was considered 
as evidence of a significant difference.31 All calculated values 
were expressed as their mean ± standard deviation.
Results and discussion
synthesis and characterization  
of the PBLg derivatives
Polymerizations were followed by FT-IR spectroscopy. 
  Disappearance of absorption bands at 1843, 1786, and 
923 cm−1, corresponding to the cyclic 5-ring anhydrides, 
indicated the end of the polymerization reaction.
1H-NMR spectroscopy of synthesized derivates confirmed 
that the expected structures were obtained for PBLG-Bnz and 
PBLG-PEG copolymers (Figure 1A, 1B). The signals at 
3.72 ppm and 7.36 ppm in the 1H-NMR spectra were attrib-
uted to the PEG backbone and aromatic methylene protons 
of polymer, respectively (Figure 1B).
High-molecular-weight polymers could be quite easily 
prepared by ring-opening polymerization in good yields International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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and large quantities. Molecular weights of the synthesized 
polymers are summarized in Table 1.
Molecular weights were calculated from viscosity 
measurements when possible, except for PBLG-PEG 
copolymers. Molecular weights for PBLG-PEG copolymers were 
calculated from 1H-NMR spectra, because the Mark–Houwink 
equation was not applicable for these PBLG derivatives. For 
this copolymer, the degree of polymerization of the PBLG seg-
ment in PBLG-PEG derivatives was determined from 1H-NMR 
spectra using the ratio between the peak intensities of methylene 
protons of the PEG chain, OCH2CH2, and the benzyl protons 
of the PBLG chain, COOCH2C6H5.  1H-NMR could not be 
used for the other PBLG derivatives because the signal from 
the polymerization initiator was difficult to localize due to the 
presence of other peaks in the same region.
Physicochemical properties  
of the nanoparticles
Stable suspensions of nanoparticles with a moderate poly-
dispersity could be easily and reproducibly prepared from 
the different synthesized PBLG derivates by a previously 
described nanoprecipitation method.27 Nanoparticles were 
typically less than 100 nm and their polydispersity index 
(PI) was typically less than 0.2. Further, these particles were 
negatively charged (zeta potential in the range of −20 mV, 
which combined with the low PI was in favor of the stability 
and homogeneity of the suspensions). These characteristics 
were compatible with an IV administration.7,8
As shown in Figure 2, the polymer concentration of the 
organic phase used during the nanoprecipitation process influ-
enced the mean diameter of the nanoparticles.   Concentrations 
were varied from 0.5 to 2.5 mg/mL while keeping the other 
processing parameters at standard   conditions. A stronger 
dependence was observed for nonpegylated nanoparticles 
for which the initial polymer concentration led to a gradual 
increase in nanoparticle diameter while maintaining a 
unimodal size distribution (PI values less than 0.2). Under 
these conditions, the average size of the nanoparticles was 
significantly increased (P , 0.05) from 60 to 100 nm in the 
case of PBLG-Bnz and 50 to 90 nm in the case of PBLG-
FITC. During the nanoprecipitation process, the mechanisms 
mastering the self-assembling of amphiphilic polymer chains 
are quite complex.   Commonly, a dependence of the size of the 
nanoparticles on the viscosity of the organic phase containing 
the polymer has been observed. For example, the importance 
of polymer concentration in controlling the size of particles 
produced by emulsification or nanoprecipitation processes 
has previously been reported for PLGA and PLA.12,32,33 
Similar results were found for polycaprolactone/PEG/ 
polycaprolactone (PCEC) nanoparticles by Huang et al.34
Interestingly, very small nanoparticles (circa 40 nm) 
were obtained from the PBLG-PEG copolymer compared 
with what was obtained with other PBLG derivatives, 
and almost no influence of the copolymer concentration 
was observed. These trends could be explained by the 
amphiphilic nature of this copolymer in comparison with 
PBLG-Bnz and PBLG-FITC, from which the nanoparticles 
were prepared without the presence of any surfactant. 
Indeed, this phenomenon could be explained by the pres-
ence of hairy PEG chains (5000 g/mol) at the surface of the 
nanoparticles extending into the water phase. Very small 
nanoparticles are of interest in targeting applications because 
the size of the nanoparticles is one of the key characteristics 
governing their traffic and their distribution in organs and 
the modalities of their capture by cells. For example, bone 
targeting requires very small particles, as it is known that 
the vasculature in bones has pores of approximately 80 nm 
in diameter.35
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Contrary to the particle size, the zeta potential was 
only slightly changed whatever the nature of the polymer 
 ( Figure 3). Pegylated nanoparticles exhibited a negative zeta 
potential value (−20 mV) closer to neutrality compared with 
nonpegylated nanoparticles (−30 mV) whatever the initial 
concentration. This trend is in agreement with other studies 
describing reductions in the zeta potential following surface 
pegylation, such as, for example, poly(alkylcyanoacrylate) 
or polylactide nanoparticles, and could be attributed to the 
shielding effect of these hydrophilic chains.36,37
Finally, storage of these preparations for 4 weeks at +4°C 
did not show any significant change in nanoparticle character-
istics (data not shown), and the suspensions remained stable.
Investigation of protein–nanoparticle 
interactions by ITc
Surface pegylation of nanoparticles aims to avoid adsorption 
of a set of serum proteins such as the complement C3b factor 
following their IV injection (opsonization), which in turn 
induces their rapid capture by the MPS. ITC analysis was per-
formed to investigate the efficiency of PEG chains to reduce 
interactions with proteins because of the hydrophilization of 
the surface of the particles and steric repulsions. As shown 
earlier by Martinez-Barbosa et al,28 ITC can be conveniently 
used for investigating this effect. In the present study, BSA 
was used for probing the capacity of PBLG nanoparticles to 
avoid interactions with proteins.
ITC experiments consist of injecting aliquots of a 
  solution containing a molecule of interest in another solution 
  containing a second molecule that is supposed to interact, or 
not, with the first one. Following each injection, heat flow 
peaks occur that correspond to the amount of heat produced 
(or   consumed) by the interaction developed between the 
two entities. When the interaction consists of an adsorption 
phenomenon, a similar behavior is expected. Indeed, as 
shown in Figure 4, enthalpograms obtained with nonpegy-
lated nanoparticles were different from those obtained with 
pegylated nanoparticles. Titration of nonpegylated nanopar-
ticles resulted in an initial series of pronounced endothermic 
peaks, which decreased in intensity after 10 injections and 
further resulted in fairly constant heat flows when adding 
BSA. This could correspond to the saturation of the surface 
in the adsorption process. On the contrary, when the BSA 
solution was injected into a suspension of pegylated nano-
particles, weaker enthalpy changes were observed than for 
nonpegylated nanoparticle injection, which could be attrib-
uted to decreased interactions of BSA with the surface of the 
nanoparticles. No significant signal was produced by dilution 
of the BSA solution in the absence of nanoparticles, which 
was used as a negative control in this experiment.
FITc labeling and characterizations  
of optimized nanoparticles
FITC-labeled nanoparticles were used for in vivo distribu-
tion studies. For this purpose, FITC-labeled nanoparticles 
were prepared from 80:20 (w/w) mixtures of PBLG-Bnz 
or PBLG-PEG with PBLG-FITC. As shown previously 
by Martinez-Barbosa et al,27,28 the nanoprecipitation of 
these copolymers leads to the production of composite 
nanoparticles, each nanoparticle simultaneously containing 
the two types of polymers. This absence of segregation could 
be attributed to the similarity of the PBLG segment in these 
copolymers. Further, it was shown that the incorporation of 
77% of PBLG-PEG copolymer chains in the nanoparticles 
was enough to maintain the “stealthiness” of the particles, 
as suggested by ITC adsorption and complementary activa-
tion measurements of Martinez-Barbosa et al.28 Thus, in the 
present experiment, an amount of 20% (w/w) of PBLG-
FITC was considered to be a good compromise for ensuring 
stealth properties in the body and simultaneously an optimal 
fluorescence labeling.
The physicochemical characteristics of these preparations 
are tabulated in Table 2. The sizes of pegylated and nonpegylated 
FITC-labeled nanoparticles were 46 ± 16 nm with a PI value 
of 0.139 ± 0.01 and 75 ± 14 nm and a narrow size distribution 
(PI = 0.114 ± 0.03), respectively. In accordance with these 
results, TEM photographs of the nanoparticles revealed ellipsoi-
0
−0.6
−0.5
−0.4
−0.3
−0.2
−0.1
0.0
50 100 150 200 250 300
Time (min)
H
e
a
t
 
f
l
o
w
 
(
µ
c
a
l
/
s
e
c
)
PBLG-Benz
Control
PBLG-PEG
Figure  4  Typical  ITc  data  corresponding  to  the  titration  of  nonpegylated 
nanoparticles  and  pegylated  nanoparticles  (2.7  ×  10−2  mM)  with  BsA  solution 
(5.4 × 10−2 mM). control consisted of the injection of BsA solution into Milli-Q® 
water. 
Abbreviations: Bnz, benzylamine; BsA, bovine serum albumin; ITc, isothermal 
titration calorimetry; PBLg, poly(γ-benzyl-L-glutamate); Peg, polyethylene glycol.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1109
Pegylation of PBLg nanoparticles
dal nanoparticles with sizes around 50 and 80 nm for pegylated 
and nonpegylated formulations, respectively (Figure 5).
Moreover, the FITC labeling efficiency was checked by 
luminescence spectrophotometer and confocal laser scan-
ning microscopy.38,39 The particles emitted green light after 
excitation at λ = 488 nm. Overall, the maximal excitation 
and emission wavelengths of formulations were found to be 
λ = 486 and λ = 515 nm, respectively, which are close to the 
values reported for free FITC.40
Fluorescence spectra and intensity were also determined 
in fresh and 4-week-old nanoparticle suspensions stored 
at +4°C in the dark. No significant differences in their 
fluorescence spectra or intensities were observed. Overall, 
maximal   excitation and emission wavelengths after storage 
of the formulations were found to be close to the values 
reported for free FITC. Such a stability of FITC fluorescence 
in PBLG nanoparticles has been reported by Segura-Sánchez 
et al, who have shown that a water suspension of fluorescent 
nanoparticles has a stable fluorescence after 200-day storage, 
although free FITC water solutions are not very stable.29 
This suggests that FITC labeling of PBLG multifunctional 
nanoparticles is of interest for visualization and tracking 
purposes.
In vivo studies
To assess the effect of size and pegylation on the distribution 
of the nanoparticles, liver and spleen were selected as 
  representative organs of the MPS.15,41,42 It is generally 
accepted that nanoparticles ranging from 30 to 100 nm in 
diameter can be captured by the macrophages of the liver 
and spleen. Liver uptake of the larger particles is faster than 
for smaller ones. Recent observations indicate that very 
small particles can pass through the sinusoidal fenestrations 
in the liver and gain access to the parenchymal cells of the 
liver.43,44 Sonavane et al prepared gold nanoparticles of differ-
ent particle sizes (15, 50, 100, and 200 nm) and distribution 
in organs like the liver, lung, and spleen and showed that 
tissue distribution of gold nanoparticles is size-dependent.45 
The smallest gold nanoparticles (15 nm) show the most 
widespread organ distribution.
The distribution of pegylated and nonpegylated (control) 
nanoparticles has been evaluated on these tissues in rats. The 
fluorescence microscopy images of liver and spleen tissue 
sections are shown in Figures 6 and 7, respectively. Twenty-
four hours after IV injection of pegylated nanoparticle sus-
pension (Figures 6C and 7C), only a negligible fluorescence 
was detected in the liver and spleen when compared with 
nonpegylated nanoparticles (Figures 6D and 7D). A strong 
green fluorescence due to the accumulation of nonpegylated 
nanoparticles could be clearly observed, especially in Kupffer 
cells, which are located mainly in the periportal region of 
Table 2 Physicochemical properties of FITc-labeled pegylated and nonpegylated nanoparticles (n = 6)
Preparation Polymer ratio 
(80% w/w)
Mean sizea 
(nm)
PI Zeta potentialb 
(mV)
Pegylated PBLg-Peg/PBLg-FITc 46 ± 16 0.139 ± 0.01 −24.5 ± 0.86
Nonpegylated PBLg-Bnz/PBLg-FITc 75 ± 14 0.114 ± 0.03 −29.8 ± 0.67
Notes: aMeasured by using a laser light scattering (Nanosize coulter N4 plus), n = 6; bMeasured by using a Zetasizer 4, n = 6. Polymer concentration for nanoprecipitation 
is 1.5 mg/mL.
Abbreviations: Bnz, benzylamine; FITC, fluorescein isothiocyanate; PBLG, poly(γ-benzyl-L-glutamate); Peg, polyethylene glycol; PI, polydispersity index.
100 nm 100 nm
A) B)
Figure 5 TeM microphotographs of FITc-labeled pegylated (A) and nonpegylated 
(B) nanoparticles.
Abbreviations:  FITC,  fluorescein  isothiocyanate;  TEM,  transmission  electron 
microscopy.
B) A)
C) D)
Figure 6 Light image of liver tissue section (A). Fluorescence images of liver tissue 
sections 24 hours after intravenous injection of: saline (B), pegylated nanoparticles 
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the liver, and few very bright spots were observed, probably 
because of aggregation. Green fluorescence along the lining 
of the liver sinusoids identified endocytosed nanoparticles 
by liver sinusoidal endothelial cells. On the contrary, the 
observed weak yellow fluorescence in tissues following 
  injection of pegylated nanoparticles suggests that pegylation 
of the PBLG nanoparticles was efficient for avoiding capture 
by the MPS. Similarly, macrophages of the spleen were much 
less deeply stained after injection of pegylated nanoparticles 
when compared with nonpegylated nanoparticles (Figure 7C 
and 7D). No autofluorescence was observed in the animals 
injected with saline, as expected (Figures 6B and 7B). It is 
evident from these results that PBLG-PEG copolymers could 
efficiently self-assemble to create a sufficient concentration 
of PEG chains at the surface of the particles, which was 
efficient for avoiding the capture of the PBLG nanoparticles 
by macrophages.
It can be concluded from this set of experimental data that 
the outer PEG layer provided an excellent stealth shield for the 
nanoparticles, while simultaneously the size of the nanopar-
ticles was small enough (46 nm) to permit the nanoparticles to 
reach tissues. Indeed, it suggests that essential properties in view 
of targeted applications can be imparted to composite nanopar-
ticles prepared by auto-assembling of PBLG derivates.
Conclusion
Due to interesting self-assembling properties, synthetic 
polypeptides deserve attention as biodegradable materials for 
the preparation of multifunctional nanoparticles. Belonging 
to this family, PBLG derivates could be synthesized using 
ring-opening polymerization, and small nanoparticles with 
stable characteristics could be successfully prepared by a 
nanoprecipitation technique without the need for surfac-
tants. Interestingly, small composite pegylated nanoparticles 
(typically 40 nm in size) made of a mixture of pegylated and 
PBLG-FITC copolymers could be obtained. The presence of 
80% of pegylated chains in the nanoparticles was enough to 
avoid their capture by the MPS, as shown by examination of 
their biodistribution in the liver and spleen. Because com-
posite PBLG nanoparticles can be looked at as an interesting 
platform for targeting applications, these preliminary results 
on the in vivo behavior of these nanoparticles are encourag-
ing and must be considered as the basis for further extensive 
exploration of the potential of these nanoparticles for targeted 
drug delivery applications.
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